Inozyme Pharma, Inc.: restructuring charge — Inozyme reports FY2024 net loss of $102M; cuts 25% workforce to focus on ENPP1 Deficiency

Inozyme Pharma, Inc.

FY2024 net loss $102.0M ($1.62 per share) vs $71.2M ($1.37 per share) in 2023.
Cash, equivalents & ST investments $113.1M; expects runway into Q1 2026 after prioritization.
Workforce reduction of ~25%; $1.8M expected charges, substantially complete by Q3 2025.
Completed enrollment in ENERGY 3 trial (N=27) for INZ-701; topline data expected Q1 2026.
ABCC6 Deficiency and calciphylaxis trials postponed; only ongoing treatment for existing patients continues.

Key facts

Extracted from this filing and checked against the source text.

Restructurings & Charges SEC 8-K Item 2.05/2.06 confidence 0.9

Inozyme Pharma, Inc. announced a restructuring with charges of approximately $1.8 million affecting all areas of the Company (approximately 25%).

Type: restructuring
Charge: approximately $1.8 million
Affected area: all areas of the Company
Headcount: approximately 25%

Exact text from the filing

On March 7, 2025, the Company's Board of Directors approved a reduction of the Company’s workforce by approximately 25% across all areas of the Company, as part of the Company’s decision to prioritize activities to support the planned Biologics License Application filing for INZ-701 for the Company’s lead indication, ENPP1 Deficiency. The Company expects to incur approximately $1.8 million in connection with the workforce reduction, which primarily represents one-time employee termination benefits directly associated with the workforce reduction.

View on SEC.gov

Browse all restructurings & charges →

Source: SEC EDGAR

accession 0000950170-25-035939

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.